Spotlight Review

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
Haematologica Early view Mar 2, 2023 https://doi.org/10.3324/haematol.2022.282612